EMA Authorised: Trixeo Aerosphere (formoterol fumarate dihydrate;glycopyrronium bromide;Budesonide) — AstraZeneca AB

View source ↗

Summary

EMA authorised Trixeo Aerosphere, a fixed-dose inhaled triple therapy of budesonide, formoterol fumarate dihydrate and glycopyrronium bromide for chronic obstru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Trixeo Aerosphere (budesonide/formoterol/glycopyrronium)

Snippet

Status: Authorised. Therapeutic area: Pulmonary Disease, Chronic Obstructive. MAH: AstraZeneca AB. Decision date: 24/07/2025